Cipher Pharmaceuticals Inc - Asset Resilience Ratio
Cipher Pharmaceuticals Inc (CPH) has an Asset Resilience Ratio of 4.80% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check strategic asset allocation of Cipher Pharmaceuticals Inc to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2025)
This chart shows how Cipher Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. See CPH equity financing ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Cipher Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Cipher Pharmaceuticals Inc stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$7.49 Million | 4.8% |
| Short-term Investments | CA$0.00 | 0% |
| Total Liquid Assets | CA$7.49 Million | 4.80% |
Asset Resilience Insights
- Limited Liquidity: Cipher Pharmaceuticals Inc maintains only 4.80% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Cipher Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Cipher Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA |
Drug Manufacturers - Specialty & Generic | 1.28% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Xeris Pharmaceuticals Inc
NASDAQ:XERS |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Procter & Gamble Health Limited
NSE:PGHL |
Drug Manufacturers - Specialty & Generic | 33.01% |
Annual Asset Resilience Ratio for Cipher Pharmaceuticals Inc (2022–2025)
The table below shows the annual Asset Resilience Ratio data for Cipher Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 4.80% | CA$7.49 Million ≈ $5.42 Million |
CA$156.22 Million ≈ $113.01 Million |
-6.18pp |
| 2024-12-31 | 10.98% | CA$17.84 Million ≈ $12.90 Million |
CA$162.51 Million ≈ $117.56 Million |
-35.32pp |
| 2023-12-31 | 46.29% | CA$39.83 Million ≈ $28.81 Million |
CA$86.03 Million ≈ $62.23 Million |
+7.21pp |
| 2022-12-31 | 39.09% | CA$28.84 Million ≈ $20.86 Million |
CA$73.78 Million ≈ $53.37 Million |
-- |
About Cipher Pharmaceuticals Inc
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead… Read more